In this study, we investigated the extent of apoptosis in 82 non-Hodgkin’s lymphoma and 4 reactive follicular hyperplasias and correlated the findings with the extent of apoptosis as determined by the 3′-end labelling method of the apoptotic DNA. To study the influence of apoptosis-regulating proteins bcl-2, bax, mcl-1 and p53 on the extent of apoptosis, we also immunostained the samples with antibodies to them. The results show that there is a significant difference in the extent of apoptosis between low- and high-grade non-Hodgkin’s lymphomas, the latter on average showing considerably more apoptotic cells (0.38 ± 0.30 and 1.44 ± 1.35%, respectively; p = 0.001). In line with this difference, high-grade lymphomas had significantly more cases with a weak expression of bcl-2 and strong expression of bax (p = 0.00008 and p = 0.016, respectively). They also showed significantly more cases with a positive p53 immunoreactivity (p < 0.00001) and strong mcl-1 immunoreactivity (p = 0.018). The results suggest that apoptosis-affecting genes bcl-2, bax, mcl-1 and p53 all take part in the regulation of apoptosis in malignant non-Hodgkin’s lymphomas and contribute to a different level of apoptosis between high- and low-grade non-Hodgkin’s lymphomas.

Keywords:
Apoptosis, Lymphoma, p53, bcl-2, bax, mcl-1
This content is only available via PDF.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.